mAbDx is pleased to announce that Michael Marusich, Ph.D., mAbDx, and Carl Hauser, M.D., Harvard, have been awarded a collaborative Mérieux Research Grant to identify new mitochondrial Damage Associated Molecular Patterns (mtDAMPs) that drive Systemic Inflammatory Response Syndrome (SIRS) after trauma. Post-trauma SIRS is a common, potentially life-threatening ...read more
mAbDx is pleased to announce it has been awarded an Oregon Venture Launch Grant to develop non-invasive (saliva-based) diagnostic tests for head and neck cancer. The award will support growth of mAbDx's pipeline of novel biomarkers and immunodiagnostics for cancer and inflammatory diseases.
Head and Neck Squamous Cell Carcinoma ...read more
The University of Oregon and mAbDx have finalized a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products. CTIP2 (also known as BCL11b) is a zinc finger transcription factor essential for transcriptional control of hundreds of genes encoding key proteins in cell signaling pathways during ...read more
mAbDx and MitoSciences/Abcam sign Master Project Agreement for mAbDx to develop medical/clinical diagnostics for: 1) sepsis, 2) SIRS (Systemic Inflammatory Response Syndrome), 3) HNSCC (Head and Neck Squamous Cell Carcinoma), 4) preeclampsia, and 5) inherited diseases affecting mitochondrial OXPHOS complexes I and IV.read more
mAbDx and the University of Oregon sign a space and care agreement to support mAbDx development of monoclonal antibodies and assays to identify and study mitochondrial DAMPs.read more
« Page 3 / 5 »